Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins.
Wang J, Saltzman AB, Jaehnig EJ, Lei JT, Malovannaya A, Holt MV, Young MN, Rimawi MF, Ademuyiwa FO, Anurag M, Kim BJ, Ellis MJ. Wang J, et al. Among authors: holt mv. Cancer Res Commun. 2023 Aug 15;3(8):1551-1563. doi: 10.1158/2767-9764.CRC-22-0501. eCollection 2023 Aug. Cancer Res Commun. 2023. PMID: 37587913 Free PMC article.
Proof-of-Concept Workflow for Establishing Reference Intervals of Human Urine Proteome for Monitoring Physiological and Pathological Changes.
Leng W, Ni X, Sun C, Lu T, Malovannaya A, Jung SY, Huang Y, Qiu Y, Sun G, Holt MV, Ding C, Sun W, Men X, Shi T, Zhu W, Wang Y, He F, Zhen B, Wang G, Qin J. Leng W, et al. Among authors: holt mv. EBioMedicine. 2017 Apr;18:300-310. doi: 10.1016/j.ebiom.2017.03.028. Epub 2017 Mar 22. EBioMedicine. 2017. PMID: 28396014 Free PMC article.
Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer.
Gou X, Kim BJ, Anurag M, Lei JT, Young MN, Holt MV, Fandino D, Vollert CT, Singh P, Alzubi MA, Malovannaya A, Dobrolecki LE, Lewis MT, Li S, Foulds CE, Ellis MJ. Gou X, et al. Among authors: holt mv. Cancer Res. 2023 Oct 2;83(19):3237-3251. doi: 10.1158/0008-5472.CAN-22-3484. Cancer Res. 2023. PMID: 37071495 Free PMC article.
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment.
Kim BJ, Zheng ZY, Lei JT, Holt MV, Chen A, Peng J, Fandino D, Singh P, Kennedy H, Dou Y, Chica-Parrado MDR, Bikorimana E, Ye D, Wang Y, Hanker AB, Mohamed N, Hilsenbeck SG, Lim B, Asirvatham JR, Sreekumar A, Zhang B, Miles G, Anurag M, Ellis MJ, Chang EC. Kim BJ, et al. Among authors: holt mv. Cancer Res Commun. 2023 Jul 26;3(7):1366-1377. doi: 10.1158/2767-9764.CRC-23-0044. eCollection 2023 Jul. Cancer Res Commun. 2023. PMID: 37501682 Free PMC article.
PKMYT1 is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer.
Chen A, Kim BJ, Mitra A, Vollert CT, Lei JT, Fandino D, Anurag M, Holt MV, Gou X, Pilcher JB, Goetz MP, Northfelt DW, Hilsenbeck SG, Marshall CG, Hyer ML, Papp R, Yin SY, De Angelis C, Schiff R, Fuqua SAW, Ma CX, Foulds CE, Ellis MJ. Chen A, et al. Among authors: holt mv. Mol Cancer Ther. 2024 May 23. doi: 10.1158/1535-7163.MCT-23-0564. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38781103
53 results